Company intelligence / Profile preview
Healx
Cambridge, England, United Kingdomhealx.ai ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Other
01
Overview
Healx’s AI-driven approach has led to FDA clearance of an IND for HLX‑1502 in neurofibromatosis type 1, now entering Phase 2 clinical trials. The company uses its proprietary AI platform to accelerate drug discovery for rare diseases by analyzing millions of data points to find new treatment opportunities using known compounds[4][5]. No published results from completed clinical trials as of May 2025.
- Therapeutic areas
- Rare Diseases
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Not specifically listed in available sources.
Beyond the preview
Go deeper on Healx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Healx.